no completed phase III human RCT for either Typical TB-500 loading dose / 2 to 5 mg subcutaneous, twice weekly for 4 to 6 weeks Typical GHK-Cu topical concentration / 1 to 4% cream or serum applied once to twice daily Typical GHK-Cu injectable dose / 0.5 to 2 mg subcutaneous, two to three times weekly Stack rationale / non-overlapping receptors allow simultaneous use without pharmacokinetic conflict Key risk / neither compound is FDA-approved for systemic use
But on the other hand, if the agency sides with the compounders and reverses its decision on tirzepatides shortage status, it risks opening itself up to lawsuits from big pharmaceutical companies like Novo Nordisk and Eli Lilly, companies whose market dominance could be undercut by the production of compounded versions and who made billions of dollars in production investments to keep up with demand
Protects Kidneys and Liver : Chronic kidney disease is a common complication of diabetes that significantly impacts patient outcomes
This not only supports overall metabolic health but can also minimize hunger that results from blood sugar fluctuations
Cholecystitis was reported by 0.8% of WEGOVY-treated pediatric patients and 0% placebo-treated patients
Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and ku70bax interaction in prostate cancer